JP2006119103A - Method for classifying pathologic conditions of renal disease - Google Patents

Method for classifying pathologic conditions of renal disease Download PDF

Info

Publication number
JP2006119103A
JP2006119103A JP2004310144A JP2004310144A JP2006119103A JP 2006119103 A JP2006119103 A JP 2006119103A JP 2004310144 A JP2004310144 A JP 2004310144A JP 2004310144 A JP2004310144 A JP 2004310144A JP 2006119103 A JP2006119103 A JP 2006119103A
Authority
JP
Japan
Prior art keywords
glomerular
urine
injury
effector
cell infiltration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2004310144A
Other languages
Japanese (ja)
Inventor
Minoru Sakazume
実 坂爪
Fumitake Shimojo
文武 下条
Kiyoko Shiba
紀代子 芝
Nobuo Hiratsuka
信夫 平塚
Takehide Matsuda
武英 松田
Akira Kubota
亮 久保田
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Niigata University NUC
Jokoh Co Ltd
Original Assignee
Niigata University NUC
Jokoh Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Niigata University NUC, Jokoh Co Ltd filed Critical Niigata University NUC
Priority to JP2004310144A priority Critical patent/JP2006119103A/en
Publication of JP2006119103A publication Critical patent/JP2006119103A/en
Pending legal-status Critical Current

Links

Images

Landscapes

  • Investigating Or Analysing Biological Materials (AREA)

Abstract

<P>PROBLEM TO BE SOLVED: To provide a method using human urine as a specimen and classifying pathologic conditions into five types which are tubulointerstitial injury, glomerular injury, without the accompanying cellular infiltration, glomerular injury accompanied by cellular infiltration, glomerular injury and tubulointerstitial injury accompanied by cellular infiltration, and non-glomerular hematuria, using three kinds analysis results of erythrocyte forms, immunocyte characters and protein fractional pathological conditions. <P>SOLUTION: Three kinds of analytical results obtained by urine analyses are classified into five kinds of pathologic conditions, in accordance with classification method shown in Figure 1, and they are utilized for predicting the diseased portions in kidney and treating renal diseases. <P>COPYRIGHT: (C)2006,JPO&NCIPI

Description

尿検査の結果により腎臓疾患の病態を分類する方法に関する技術分野 Technical field related to methods of classifying kidney disease pathology based on urinalysis results

従来より、尿中赤血球形態検査は位相差顕微鏡で行われていた。検出感度が低く、腎糸球体疾患か泌尿器系疾患による出血かの判定が困難であった。最近特許文献1、2及び3に示されたようなレーザー散乱光を用いる尿中赤血球形態検査の自動化機器により細かく形態分類が出来るようになり日常的に使用されつつある。腎疾患の診断はこれら血液の形態学的な測定結果からだけで行われるものではなく、別の検査法による診断も合わせて試みられるようになってきた。それは特許文献4に示すような尿蛋白分画により糸球体性腎障害か尿細管性腎障害かを分類する病態分類法である。その他リンパ球の表面形質を調べる方法として蛍光標識抗体を使うフローサイトメトリー法(FACS法)により、炎症性細胞の浸潤が活発になっているかどうかも検査法として確立された(非特許文献1)。さらに腎疾患の診断については、これらの検査法のほか、腎組織を採取(腎生検という)して病理学的な検査法を併用して最終的に診断がなされていた。しかし、腎生検は侵襲的な検査であり、死亡例を含めた合併症が報告されていて、昨今の医療事情からこの検査実施には厳しい適応症例の選択がなされるようになっている。
特開平8-240520号公報 特開平11-295207号公報 特開平11-118793号公報 特願2003-367424号公報 J Am Soc Nephrol 12: 2636-2644,2001
Conventionally, urine erythrocyte morphology has been examined with a phase contrast microscope. Detection sensitivity was low, and it was difficult to determine whether it was due to renal glomerular disease or urinary tract disease. Recently, the automatic urine erythrocyte morphology test apparatus using laser scattered light as disclosed in Patent Documents 1, 2, and 3 has become capable of finely classifying morphologies and is being used on a daily basis. Diagnosis of kidney disease is not only made from the morphological measurement results of these blood, but has also been tried together with diagnosis by another test method. It is a pathological classification method for classifying glomerular renal disorder or tubular renal disorder by urine protein fraction as shown in Patent Document 4. As a method for examining surface characteristics of lymphocytes, whether or not infiltration of inflammatory cells is active has been established by a flow cytometry method (FACS method) using a fluorescently labeled antibody (Non-patent Document 1). . Furthermore, regarding the diagnosis of kidney disease, in addition to these examination methods, kidney tissue was collected (referred to as renal biopsy) and finally used in combination with pathological examination methods. However, renal biopsy is an invasive examination, and complications including death cases have been reported, and due to recent medical circumstances, severely applicable cases have been selected for conducting this examination.
JP-A-8-240520 Japanese Patent Laid-Open No. 11-295207 Japanese Patent Laid-Open No. 11-118793 Japanese Patent Application No. 2003-367424 J Am Soc Nephrol 12: 2636-2644,2001

腎疾患の診断は、従来の技術で述べたような今まで独立してそれぞれの検査結果を、医師が自分の経験で診断していたが、本願発明ではそれらの検査結果を組み合わせることで非侵襲的に腎疾患の病態診断に役立てることを目的とした。 In the diagnosis of kidney disease, doctors have independently diagnosed each test result as described in the prior art until now, but in the present invention, these test results are combined to make non-invasive. The purpose was to make use of it for the diagnosis of renal diseases.

今までは、これら検査法の結果に基づいて医師により総合的に診断を行っていたが、本願発明ではそれら検査法をコンピュータの画像解析や統計的手法により腎疾患の病態を分類し診断に役立つ情報を提供できる方法を提示した。この課題を解決するため、多数の臨床例を用い、それぞれの検査法を比較検討しかつ腎生検による臨床診断に基づき腎疾患の病態を把握できるようになる方法を発明した。この結果、腎生検をしなくともおおよその診断が出来るようになった。詳細は下記のとおりである。 Until now, doctors have comprehensively diagnosed based on the results of these examination methods. In the present invention, these examination methods are useful for diagnosis by classifying the pathological conditions of renal diseases by computer image analysis and statistical methods. A method that can provide information is presented. In order to solve this problem, a method has been invented in which a number of clinical cases are used, the respective examination methods are compared and examined, and the pathological condition of renal disease can be grasped based on clinical diagnosis by renal biopsy. As a result, an approximate diagnosis can be made without performing a renal biopsy. Details are as follows.

一般的に、腎臓の機能から赤血球や蛋白質の出現は無いものとされており、尿中赤血球、尿中免疫細胞、尿蛋白質の出現そのものが腎機能の障害すなわち腎疾患を予測させるものである。その腎疾患のうち、腎糸球体障害としてはIgA腎症、膜性腎症、半月体形成性腎炎、巣状糸球体硬化症などが知られている。また腎尿細管障害としてはファンコニー症候群、間質性腎炎などがある。 In general, red blood cells and proteins do not appear due to kidney function, and the appearance of urinary red blood cells, urinary immune cells, and urine protein itself is a predictive disorder of renal function, that is, renal disease. Among the kidney diseases, IgA nephropathy, membranous nephropathy, crescent nephritis, focal glomerulosclerosis and the like are known as renal glomerular disorders. Examples of renal tubular disorders include Fancony syndrome and interstitial nephritis.

腎疾患の確定診断には、腎生検が広く行われている。腎生検とは針を患者の腎臓に向かって穿刺し、腎組織を取り出し病理組織標本を作製し染色後専門医による病理診断をする方法であり、患者にかなりの苦痛を与えるばかりか死亡例を含む合併症の報告もあり、組織の採取や病理組織標本の作製、その標本の読取や判定に相当の費用と時間と熟練を要していた。 Renal biopsy is widely used for definite diagnosis of kidney disease. Renal biopsy is a method in which a needle is punctured toward a patient's kidney, a renal tissue is taken out, a histopathological specimen is prepared, and a pathological diagnosis is performed by a specialist after staining. There are also reports of complications, and considerable cost, time, and skill were required for collecting tissues, preparing pathological tissue specimens, and reading and judging the specimens.

さらに患者の臓器の一部を取り出すため周りの組織に少なからずの障害を与えるため、肉眼的血尿、血腫の形成など出血にまつわる合併症が起こり、出血の程度が多ければ血圧低下、ショック、そして死亡に至ることがある。 In addition, some of the patient's organs are removed, causing damage to surrounding tissues, resulting in complications related to bleeding such as gross hematuria and hematoma formation. If bleeding is severe, blood pressure drops, shock, and death May lead to.

本願発明は、前述特許文献1、2、3および4や非特許文献1など多くの検査法の結果および腎生検と高感度の尿蛋白質電気泳動像の臨床例をそれぞれ詳しく精査した結果、3種類の非浸襲の尿の検査法を組み合わせることで、疾患を5群に分類しその群特有のアルゴリズムをコンピュータにより病態解析を行い、それが非常に有用という結論に至った。 The present invention is based on the results of many examination methods such as the aforementioned Patent Documents 1, 2, 3 and 4 and Non-Patent Document 1, and the results of detailed examination of clinical examples of renal biopsy and highly sensitive urinary protein electrophoresis images. By combining various types of non-invasive urine testing methods, the disease was classified into 5 groups, and the pathological analysis of the algorithm specific to that group was performed by a computer, and it was concluded that it was very useful.

3種類の検査法は下記の通りである。 The three types of inspection methods are as follows.

最初の検査法は、尿赤血球は特許文献1及び2及び3に示されたようなレーザー散乱光を用いる尿中赤血球形態検査の自動機により、赤血球形態を判定し赤血球が変形しているか、またはしていないかを分類する。赤血球の変形とは、糸球体毛細血管壁の断裂などの病的変化部分を赤血球が通過するため、一部破砕されたりすることで生ずると考えられている。また、その後尿細管を通過する際に、尿の浸透圧変化によって金平糖状などに形が変化したものである。一方、変形のない正常の赤血球とは、このような変化を伴わず、下部尿路からの出血を意味する。 The first examination method is that urine red blood cells are deformed by determining the red blood cell morphology by an automatic urine red blood cell morphology test using laser scattered light as shown in Patent Documents 1 and 2 and 3, or Categorize whether or not The deformation of erythrocytes is considered to occur when the erythrocytes are partially crushed because the erythrocytes pass through pathological changes such as rupture of the glomerular capillaries. Further, when passing through the tubule after that, the shape is changed to a confetti shape due to a change in osmotic pressure of urine. On the other hand, normal erythrocytes without deformation means bleeding from the lower urinary tract without such changes.

次の検査法は、尿中免疫細胞の検査法で、FACS法と言い出現した細胞表面の形質を解析し、エフェクター細胞か非エフェクター細胞かを分類する。 The next test method is a test of immune cells in urine, which is called FACS method and analyzes the appearance of cell surface and classifies it as effector cells or non-effector cells.

エフェクター細胞とは単球・リンパ球などの免疫細胞の表面抗原のうちCD62Lが陰性のもので、リンパ球は同時にCD45RO陽性、CD45RA陰性である。これらのエフェクター細胞は組織障害を引き起こす活性化された細胞であり、腎炎の浸潤細胞も同じ表現型を示す。尿のエフェクター細胞は、腎の炎症細胞が腎糸球体毛細血管の破壊などで腎組織を障害した結果、尿中に現れたものと考えられる(非特許文献1)。一方、非エフェクター細胞はCD62Lが陽性のもので、リンパ球は同時にCD45RO陰性、CD45RA陽性である。無害の非活性化細胞であり、健常者の末梢血中の免疫細胞の大部分はこの表現型を示す。 Effector cells are surface antigens of immune cells such as monocytes and lymphocytes that are negative for CD62L, and lymphocytes are simultaneously CD45RO positive and CD45RA negative. These effector cells are activated cells that cause tissue damage, and nephritic infiltrating cells also show the same phenotype. Urinary effector cells are thought to have appeared in urine as a result of renal inflammatory cells damaging renal tissue, such as by destroying renal glomerular capillaries (Non-patent Document 1). On the other hand, non-effector cells are positive for CD62L, and lymphocytes are simultaneously negative for CD45RO and positive for CD45RA. Harmless non-activated cells, the majority of immune cells in the peripheral blood of healthy individuals exhibit this phenotype.

3番目の検査法は、セルロース・アセテート膜を支持体とした患者尿蛋白質を電気泳動するもので、その超微量蛋白質を銀染色液で検出した後、特許文献4に示された方法に基づいて、糸球体障害パターン、尿細管障害パターン、混合パターンに分類する。 The third method is to perform electrophoresis of patient urine protein using cellulose acetate membrane as a support. After detecting the ultra-trace amount of protein with silver stain, it is based on the method shown in Patent Document 4. Classify into glomerular damage pattern, tubule damage pattern, and mixed pattern.

糸球体障害パターンとは、アルブミン画分とβ画分の分画値がそれぞれその他の疾患群の分画値に較べて、有意に高く現れることを特長とした群をいう。 The glomerular injury pattern refers to a group characterized in that the fraction values of the albumin fraction and the β fraction appear significantly higher than the fraction values of the other disease groups, respectively.

尿細管障害パターンとは、アルブミン画分の分画値が腎糸球体障害を主とする群のアルブミン画分の分画値より有意に低くかつ、β画分の代わりにそれをはさんだ形に別の蛋白画分が有意に濃く現れることを特長とした群をいう。 The tubule injury pattern is that the fraction value of the albumin fraction is significantly lower than the fraction value of the albumin fraction of the group mainly composed of renal glomerular disorders and is sandwiched between them instead of the β fraction. A group characterized by the fact that another protein fraction appears significantly darker.

混合パターンとは上記の糸球体障害パターンと尿細管障害パターンが両方とも見られるものをいう。 The mixed pattern refers to a pattern in which both the glomerular damage pattern and the tubular damage pattern are seen.

3種類の検査法を組み合わせした尿疾患に関する病態解析のアルゴリズムは下記のとおりとした。 The pathological analysis algorithm for urinary disease combining three types of testing methods was as follows.

尿中に赤血球が有り、その赤血球の形が正常な場合をR1、形が変形している場合をR2、尿中に赤血球が見られない場合をR3とし、尿中に免疫細胞である非エフェクター細胞が見られる場合をI1、エフェクター細胞が見られる場合をI2、尿中に免疫細胞が見られない場合をI3とした。また、尿蛋白病態分類において糸球体障害パターンをP1、尿細管障害パターンをP2、混合型をP3とする。 Non-effector that is an immune cell in urine, with R1 when there are red blood cells in the urine and the shape of the red blood cells is normal, R2 when the shape is deformed, and R3 when no red blood cells are seen in the urine The case where cells were seen was designated as I1, the case where effector cells were seen as I2, and the case where immune cells were not found in urine as I3. In the urine protein pathological classification, the glomerular damage pattern is P1, the tubular damage pattern is P2, and the mixed type is P3.

上記の組み合わせにより、下記のようなA〜E型の障害部位を検査することができる。 According to the above combination, the following A to E type damaged sites can be examined.

A型 尿細管間質障害・・・R3、I2、P2の組み合わせで、 関係する疾患は尿細管間質性腎炎などがある。 Type A tubulointerstitial disorder: a combination of R3, I2, and P2, and related diseases include tubulointerstitial nephritis.

糸球体毛細血管の破壊・断裂などの糸球体障害がないためR3の変形赤血球がなく、尿細管間質にエフェクター細胞の浸潤とそれによる尿細管の破壊が考えられI2のエフェクター細胞が現れる。その結果P2の尿蛋白尿細管障害パターンを示し、尿細管性蛋白尿が出現する。 Since there is no glomerular injury such as glomerular capillary destruction / rupture, there is no deformed red blood cell of R3, and infiltration of effector cells into the tubulointerstitium and consequent destruction of the tubules is considered, and I2 effector cells appear. As a result, urinary protein tubule injury pattern of P2 is shown, and tubular proteinuria appears.

B型 細胞浸潤を伴わない糸球体障害・・・R3、I3、P1の組み合わせで、 関係する疾患は微小変化型、膜性腎症、糸球体肥大などがある。 B-type glomerular disorder without cell infiltration: a combination of R3, I3, and P1, and related diseases include micro-variable, membranous nephropathy, and glomerular hypertrophy.

炎症細胞による糸球体毛細血管の破壊・断裂などの糸球体障害がないのでR3の変形赤血球がなく糸球体から蛋白が漏出する障害があるためP1の尿蛋白糸球体障害パターンを示す。またI3のエフェクター細胞ないことから腎組織での炎症性細胞浸潤がない。 Since there is no glomerular damage such as destruction or rupture of glomerular capillaries by inflammatory cells, there is no deformed erythrocyte of R3, and there is a problem of protein leakage from the glomeruli, indicating a urinary protein glomerular damage pattern of P1. In addition, since there is no effector cell of I3, there is no inflammatory cell infiltration in renal tissue.

C型 細胞浸潤を伴う糸球体障害・・・R2、I2、P1の組み合わせで関係する疾患はIgA腎症、ANCA関連腎炎などの半月体形成性腎炎などがある。 Glomerular disorder with type C cell infiltration: Diseases related to the combination of R2, I2, and P1 include IgA nephropathy and crescent-forming nephritis such as ANCA-related nephritis.

炎症細胞による糸球体毛細血管の破壊・断裂などの糸球体障害があるためR2の変形赤血球があり、糸球体から蛋白が漏出する障害もあるため、P1の尿蛋白糸球体障害パターンを示す。またI2のエフェクター細胞があり、腎組織での炎症性細胞浸潤が示唆される。 Since there are glomerular disorders such as destruction and rupture of glomerular capillaries by inflammatory cells, there are deformed erythrocytes of R2, and there is also a disorder of protein leakage from the glomeruli. There are also I2 effector cells, suggesting inflammatory cell infiltration in renal tissue.

D型 細胞浸潤を伴う尿細管間質障害・・・R2、I2、P2あるいは P3の組み合わせで 関係する疾患は尿細管間質腎炎(TIN)を伴うANCA関連腎炎などがある。 D-tubulointerstitial disorder with cell infiltration: Diseases associated with R2, I2, P2 or P3 combinations include ANCA-associated nephritis with tubulointerstitial nephritis (TIN).

炎症細胞による糸球体毛細血管の破壊・断裂などの糸球体障害があるためR2の変形赤血球があり、P2あるいはP3の尿蛋白尿細管障害パターンのみ、あるいは尿蛋白尿細管障害パターンがありかつ尿蛋白糸球体障害パターンを示すため、小分子蛋白の再吸収障害がありその後障害の進展で糸球体から蛋白が漏出する。またこの型は、腎組織での炎症性細胞浸潤が示唆されるためI2のエフェクター細胞も見られる。 R2 deformed red blood cells due to glomerular damage such as destruction and rupture of glomerular capillaries by inflammatory cells, P2 or P3 urine protein tubule injury pattern only, urine protein tubule injury pattern and urine protein In order to show a glomerular damage pattern, there is a reabsorption disorder of small molecule protein, and then protein leaks from the glomerulus as the damage progresses. In addition, this type suggests inflammatory cell infiltration in kidney tissue, and I2 effector cells are also found.

E型 非糸球体性血尿・・・R1、I1の組み合わせで 関係する疾患は尿路出血、特発性腎出血などがある。 Type E non-glomerular hematuria ・ ・ ・ R1 and I1 related diseases include urinary tract bleeding and idiopathic renal bleeding.

糸球体毛細血管の破壊・断裂などの糸球体障害がないためR3の変形赤血球もなく、赤血球は末梢血型であり、尿免疫細胞も末梢血型であるためI1の非エフェクター細胞が存在する。 Since there is no glomerular damage such as glomerular capillary destruction / rupture, there is no deformed red blood cell of R3, red blood cells are peripheral blood types, and urine immune cells are also peripheral blood types, so there are non-effector cells of I1.

今まで腎生検は、診断に不可欠なものとされている。これは患者の腎臓に生検針を刺し、腎組織を採取しなければならないので侵襲的であり、当然患者に苦痛を強いることになる。また正常な細胞を傷つけることにもなっている。さらに採取した腎組織は専門技術者により病理標本作成に数日間を要し、さらに専門医による標本の顕微鏡診断を必要としている。 Until now, renal biopsy has been considered essential for diagnosis. This is invasive because the patient's kidney must be pierced with a biopsy needle and the kidney tissue must be collected, which naturally hurts the patient. It also damages normal cells. In addition, the collected kidney tissue requires several days for the preparation of a pathological specimen by a specialist engineer, and further requires microscopic diagnosis of the specimen by a specialist.

本願発明が果たす役割は主に2つの側面を持っており、その1つは、腎疾患の早期発見が可能になり、早急に治療を要する患者をいち早く抽出できることにある。今までは時間的制約・コストの制約・患者が多すぎるなどの制約のため、唯一の診断的検査であった腎生検が行えずに放置されていた患者を救うことになる。 The role played by the present invention mainly has two aspects. One of them is that early detection of a renal disease is possible, and patients who need treatment can be quickly extracted. Up to now, due to constraints such as time constraints, cost constraints, and too many patients, patients who have been left without a renal biopsy, which was the only diagnostic test, will be saved.

2つめは、腎生検に代わって大まかな腎疾患の病態診断を行えることである。腎生検は危険を伴い費用や時間が掛かるが、本願発明を活用して、腎生検を行うことなく疾病が進行する前に治療を開始することで、疾患の治癒を早めたり透析開始時期を遅らせたりする事が可能となる。 Secondly, it is possible to perform a rough pathological diagnosis of kidney disease instead of a renal biopsy. Renal biopsy is dangerous and costly and time consuming, but by using the present invention to start treatment before the disease progresses without performing renal biopsy, it is possible to accelerate disease healing or start dialysis Can be delayed.

細分化された診断技術は、例えはIgA腎症、透析、糖尿病、糸球体腎症、自己免疫疾患など多彩な専門的技術の積み重ねにより成り立ってきており、専門医さえ戸惑うことがあるという時代、診断の見逃しはあってはならない事態であるが、本願発明はこれらの診断に側面から支援するものとなる。 Subdivided diagnostic technology is based on the accumulation of various specialized technologies such as IgA nephropathy, dialysis, diabetes, glomerulonephropathy, and autoimmune diseases. Although this situation should not be overlooked, the present invention supports these diagnoses from the aspect.

早期診断による早期治療は、治癒率が飛躍的に向上する。また治療効果が及ばずに病気が進行した場合でも、人工透析開始時期を遅らせたり、病態の悪化を防ぐ事が出来るため、結果的に医療費の低減が図れる。 Early treatment by early diagnosis dramatically improves the cure rate. Moreover, even when the disease progresses without reaching the therapeutic effect, the start time of the artificial dialysis can be delayed and the deterioration of the disease state can be prevented, so that the medical cost can be reduced as a result.

採尿後、特許文献1、2、3に記されている尿赤血球分析装置により赤血球形態を判定し、次に尿沈渣と上清を遠心分離し、沈渣は非特許文献1に記されているリンパ球・単球をFACS法により表面形質を解析した。上澄はセルロース・アセテート膜電気泳動で尿蛋白分画を行ない、特許文献4の方法で分類しさらに本願発明の前述したアルゴリズムで病態分類した。 After collecting urine, erythrocyte morphology is determined by the urine erythrocyte analyzer described in Patent Documents 1, 2, and 3, and then urine sediment and supernatant are centrifuged. Surface traits of spheres and monocytes were analyzed by FACS method. The supernatant was subjected to urine protein fractionation by cellulose acetate membrane electrophoresis, classified by the method of Patent Document 4, and further classified by the above-described algorithm of the present invention.

尿中に赤血球が有り、その赤血球の形が正常な場合をR1、形が変形している場合をR2、尿中に赤血球が見られない場合をR3とし、尿中に免疫細胞である非エフェクター細胞が見られる場合をI1、エフェクター細胞が見られる場合をI2、尿中に免疫細胞が見られない場合をI3とした。また、尿蛋白病態分類において糸球体障害パターンをP1、尿細管障害パターンをP2、混合型をP3とした。
上記の組み合わせにより、図1のようにA〜E型の障害部位を分類することができた。なおA〜E型の障害部位の分類の名称は、それぞれ固有の名称に変えても差し障りが無い。
Non-effector that is an immune cell in urine, with R1 when there are red blood cells in the urine and the shape of the red blood cells is normal, R2 when the shape is deformed, and R3 when no red blood cells are seen in the urine The case where cells were seen was designated as I1, the case where effector cells were seen as I2, and the case where immune cells were not found in urine as I3. In the classification of urinary protein pathology, the glomerular damage pattern was P1, the tubular damage pattern was P2, and the mixed type was P3.
According to the above combinations, the A to E type lesions could be classified as shown in FIG. It should be noted that there is no problem even if the names of the A to E type faulty sites are changed to unique names.

尿検査病態分類表Urinalysis pathology classification table

Claims (6)

ヒトの尿の分析結果により、尿細管間質障害と、細胞浸潤を伴わない糸球体障害と、細胞浸潤を伴う糸球体障害と、細胞浸潤を伴う糸球体障害・尿細管間質障害と、非糸球体性血尿の5病態を分類する方法 According to human urine analysis results, tubulointerstitial disorders, glomerular disorders without cell infiltration, glomerular disorders with cell infiltration, glomerular and tubulointerstitial disorders with cell infiltration, non- How to classify the five pathologies of glomerular hematuria 尿細管間質障害の病態を把握する方法として、尿赤血球が有意に無いこと及びエフェクター型免疫細胞が有意にありかつ尿蛋白電気泳動像が尿細管性像を示すことを特長とする請求項1の病態分類法 2. The method for grasping the pathophysiology of tubulointerstitial disorder is characterized in that urine erythrocytes are not significantly present, effector type immune cells are significantly present, and urinary protein electrophoretic images show tubular images. Classification of disease states 細胞浸潤を伴わない糸球体障害の病態を把握する方法として、尿赤血球が有意に無いこと及びエフェクター型免疫細胞が有意に無くかつ尿蛋白電気泳動像が糸球体性像を示すことを特長とする請求項1の病態分類法 As a method of grasping the pathology of glomerular injury without cell infiltration, it is characterized by the absence of urine red blood cells, the absence of effector-type immune cells, and the urinary protein electrophoresis image showing glomerular image The pathological classification method of claim 1 細胞浸潤を伴う糸球体障害を把握する方法として、尿赤血球が有意にあり変形していること及びエフェクター型免疫細胞が有意数ありかつ尿蛋白電気泳動像が糸球体性像を示すことを特長とする請求項1の病態分類法 As a method of grasping glomerular injury accompanied by cell infiltration, urine erythrocytes are significantly deformed, there are significant number of effector type immune cells, and urine protein electrophoresis image shows glomerular image The pathological classification method of claim 1 細胞浸潤を伴う糸球体障害・尿細管間質障害の病態を把握する方法として、尿赤血球が有意に存在しかつ変形していること及びエフェクター型免疫細胞が有意数ありかつ尿蛋白電気泳動像が混合型あるいは尿細管性像を示すことを特長とする請求項1の病態分類法 As a method of grasping the pathophysiology of glomerular injury and tubulointerstitial injury associated with cell infiltration, urine erythrocytes are significantly present and deformed, there are a significant number of effector-type immune cells, and urine protein electrophoresis images 2. The pathological classification method according to claim 1, characterized in that it shows a mixed or tubular image 非糸球体性血尿の病態を把握する方法として、尿赤血球が有意に存在しかつ変形していないこと及び非エフェクター型免疫細胞が有意数ありかつ尿蛋白電気泳動像が血清と同じ像を示すことを特長とする請求項1の病態分類法 Non-glomerular hematuria as a method of understanding the pathology of urine erythrocytes is significantly present and untransformed, non-effector immune cells are significant, and urine protein electrophoresis images show the same image as serum The pathological classification method of claim 1 characterized by
JP2004310144A 2004-10-25 2004-10-25 Method for classifying pathologic conditions of renal disease Pending JP2006119103A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2004310144A JP2006119103A (en) 2004-10-25 2004-10-25 Method for classifying pathologic conditions of renal disease

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2004310144A JP2006119103A (en) 2004-10-25 2004-10-25 Method for classifying pathologic conditions of renal disease

Publications (1)

Publication Number Publication Date
JP2006119103A true JP2006119103A (en) 2006-05-11

Family

ID=36537112

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2004310144A Pending JP2006119103A (en) 2004-10-25 2004-10-25 Method for classifying pathologic conditions of renal disease

Country Status (1)

Country Link
JP (1) JP2006119103A (en)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009204465A (en) * 2008-02-28 2009-09-10 Jokoh Co Ltd Method for determining pathology of kidney disease or like by electrophoretic method using silver staining
JP2010237001A (en) * 2009-03-31 2010-10-21 Sysmex Corp Renal disease diagnosis support apparatus and computer program
JP2010236863A (en) * 2009-03-30 2010-10-21 Sysmex Corp Urine sample analyzer
CN109165544A (en) * 2018-07-05 2019-01-08 丁彦青 Training method, diagnostic equipment and the storage medium of glomerulonephritis pathology Intelligence Classifier

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009204465A (en) * 2008-02-28 2009-09-10 Jokoh Co Ltd Method for determining pathology of kidney disease or like by electrophoretic method using silver staining
JP2010236863A (en) * 2009-03-30 2010-10-21 Sysmex Corp Urine sample analyzer
JP2010237001A (en) * 2009-03-31 2010-10-21 Sysmex Corp Renal disease diagnosis support apparatus and computer program
CN109165544A (en) * 2018-07-05 2019-01-08 丁彦青 Training method, diagnostic equipment and the storage medium of glomerulonephritis pathology Intelligence Classifier

Similar Documents

Publication Publication Date Title
Sugimoto et al. What is the nature of pancreatic consistency? Assessment of the elastic modulus of the pancreas and comparison with tactile sensation, histology, and occurrence of postoperative pancreatic fistula after pancreaticoduodenectomy
Davidson et al. Macroenzyme detection by polyethylene glycol precipitation
Dargazanli et al. High CD3+ cells in intracranial thrombi represent a biomarker of atherothrombotic stroke
Loyola-Leyva et al. Morphological changes in erythrocytes of people with type 2 diabetes mellitus evaluated with atomic force microscopy: A brief review
Balabanova et al. A study of the cutaneous manifestations of Behçet's disease in patients from the United States
Potlog-Nahari et al. CD10 immunohistochemical staining enhances the histological detection of endometriosis
Jain et al. Rapid evaluation of fresh ex vivo kidney tissue with full-field optical coherence tomography
Zeng et al. Urinary β2-microglobulin is a sensitive indicator for renal tubular injury
Westermark Diagnosing amyloidosis
Zwi et al. Non-diabetic renal diseases in a multi-ethnic New Zealand cohort with type 2 diabetes mellitus: clinical and histopathological features
JP2006119103A (en) Method for classifying pathologic conditions of renal disease
Siwaponanan et al. Enumeration and phenotyping of circulating microvesicles by flow cytometry and nanoparticle tracking analysis: Plasma versus serum
RU2469324C1 (en) Method for assessment of gastric mucosa state in children
Kangari et al. Predictive accuracy of urinary β2-microglobulin for kidney injury in children with acute pyelonephritis.
CN108728400A (en) A kind of Chronic glomerular disease glomerulosclerosis marker and its detection kit
Zhang et al. Exploration of noninvasive detection of advanced glycation end products in the lens to screen for diabetic kidney disease
KATİCA et al. The role of organic urine sediment analysis in the monitoring of renal diseases
JP4825828B2 (en) Method for determining pathological conditions such as renal diseases by electrophoresis using silver staining
US20210041336A1 (en) Method and system for evaluating fertility of human spermatozoa
JP4487081B2 (en) Activity determination method and apparatus for renal disease
Steinmetz et al. Stepwise strategies in analysing haematuria and leukocyturia in screening
CN108426862A (en) A method of differentiating that liver cancer breaks up grade using multi-photon imaging technique
RU2199117C2 (en) Method for diagnosing the cases of hypospermatogenesis and spermatogenic testicular cells atrophy
Hassaan et al. Fatty Acid Binding Protein (1 & 2) as Markers of Diabetic Nephropathy in Elderly Patients with Type 2 Diabetes Mellitus
RU2616904C1 (en) Method of determination of myocardial infarction in the conducting of forensical-medical expertise

Legal Events

Date Code Title Description
A521 Written amendment

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20060310

A521 Written amendment

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20060310

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20071015

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20080526

A521 Written amendment

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20080723

A521 Written amendment

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20080830

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20081125

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20090330